Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-Cell or B-Cell Precursor Acute Lymphoblastic Leukaemia or T-Cell Non-Hodgkin's Lymphoma.

Next Previous
Search
Trial Profile

A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-Cell or B-Cell Precursor Acute Lymphoblastic Leukaemia or T-Cell Non-Hodgkin's Lymphoma.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Forodesine (Primary) ; Forodesine (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Mundipharma International

    • Most Recent Events

    • 30 Jul 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.
    • 24 Mar 2012 This trial is recruiting in France.
    • 17 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top